AI FOR SCIENCE · ON THE RECORD
Ligo Biosciences
Designs enzymes with its own models, Artios for the protein backbone and the sequence, and tests the designs in its own lab; it built BioBasicsBench, a wet-lab data benchmark, with OpenAI.
Full funding record →On the timeline →People filter →
Timeline
- 2026-11-06OpenAI and Ligo's BioBasicsBench scores AI agents on 100 tasks built from real wet-lab data, and GPT-6 Astra earns 66.7% of
the points Level 2 · Computed - 2026-10-20Ligo Biosciences' Artios designed esterases from scratch, and 17 of 88 were active in the company's
own screen Level 4 · Tested in the physical world
Graded by how far the evidence went, not how good the result is. See
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Arda GoreciFounder Ligo Biosciences' Artios designed esterases from scratch, and 17 of 88 were active in the company's own screen
Edward HarrisFounder Ligo Biosciences' Artios designed esterases from scratch, and 17 of 88 were active in the company's own screen
Emily Egerton-WarburtonFounder Ligo Biosciences' Artios designed esterases from scratch, and 17 of 88 were active in the company's own screen- OOliver CortBuilt the computational system and trained the models, as the Artios paper's contributors section states Ligo Biosciences' Artios designed esterases from scratch, and 17 of 88 were active in the company's own screen
Funding rounds tracked
- 2024-08-16Accelerator (Y Combinator, Summer 2024) · Y Combinator backing; amount not statedconfirmedWith Y Combinator
Each round links to its line on the funding record, with its source.
Also in Protein design on the funding board
The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.
- 2026-11-09Tushen ZhihePre-A and Pre-A+ · several hundred million yuan across two roundsDesigns and optimises proteins, antibodies and cyclic peptides with its own and adapted open models on the ToursynClaw platform, tests them in automated wet labs, and is taking its own programmes toward IND filings.
- 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
- 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
- 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
- 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
- 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.